AIM Immunotech

AIM ImmunoTech is a clinical-stage immuno-pharma company whose research and development pipeline is centered on its lead drug candidate, Ampligen (rintatolimod). The development of pharmaceutical products, including Ampligen, requires preclinical safety and efficacy testing to meet regulatory requirements for human clinical trials. This development pathway inherently involves animal testing as a standard component of the investigational new drug (IND) application process submitted to the U.S. Food and Drug Administration.

The company’s public disclosures and clinical trial announcements confirm its active engagement in this regulated development process. AIM has reported positive preclinical data for Ampligen across multiple proposed indications, including pancreatic cancer and Ebola, and has secured FDA designations such as Orphan Drug status. These milestones are predicated on a foundation of animal studies to establish initial safety and biological activity. As a company whose sole business is the development of novel therapeutics, AIM ImmunoTech’s operations are fundamentally reliant on animal testing to advance its product candidates through the regulatory pipeline.